Antimicrobial Stewardship (AMS) is the means to fight against antimicrobial resistance (AMR). To help ensure antibiotics remain effective, hospital-based stewardship programs promote and monitor their appropriate use. AMS therefore helps fight the rise of Multidrug Resistant Organisms (MDRO) and prevents outbreaks of healthcare-acquired infections (HAI). Diagnostics are a key part of AMS programs. They provide information, data and results throughout the patient pathway.
Do you need more information?
What is Antimicrobial Resistance (AMR) ?
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others.
How does Antibiotic resistance occur ?
The development of resistant bacteria is a natural phenomenon that is exacerbated and accelerated by the inappropriate use of antibiotics in the fields of human and animal health and the inadequate infection control.
The cost is high, If we do not address AMR now
Every 45 seconds someone dies from an infection caused by a resistant bacteria
Source: WHO (October 27th)
Act now: It’s the only way we will reduce the threat of resistance
Antimicrobial Stewardship (AMS) is critical to fight the AMR crisis. AMS programs help fight antimicrobial resistance by providing a framework for responsible antibiotics prescribing and use, optimizing individual therapy, helping reduce the spread of resistance and raising awareness & education.
bioMérieux: your partner of choice on AMS
Put diagnostics at the heart of Antimicrobial Stewardship to drive informed therapy decisions.
bioMérieux has the most comprehensive solutions on the market all along the patient pathway:
Product availability varies by country. Consult your bioMérieux sales representative.
Our complete AMS solution encompasses more than just traditional state-of-the-art lab technology. Because at bioMérieux we fully understand your antimicrobial stewardship (AMS) needs our offer translates into 4 key areas where we help hospitals and labs worldwide evolve to suit today’s needs and tomorrow’s concerns:
Provide fast and actionable infectious disease diagnostic tools to support responsible use of antimicrobials from antibiotics initiation, to optimization, to discontinuation
Gain a holistic view and start connecting diagnostics to therapeutic decisions and connect the decisions to outcomes
Improve lab efficiency and accelerate the medical and economic value of stewardship
Educate hospital stakeholders to ensure Antimicrobial Stewardship programs success
How can we help the lab?
We accompany you with a tailored offer to leverage your diagnostic expertise and ensure clinicians optimize therapy sooner. bioMérieux can support you to provide relevant laboratory data to optimize antibiotic therapy
Provide up-to-date Antibiogram Reports to help empiric therapy decisions
|BIOMERIEUX LAB CONSULTANCY
Reduce time-to-results by streaming processes and optimizing resource use
|VIDAS BRAHMS PCT
Evaluate whether to start antibiotic therapy and establish a baseline for monitoring patient response to antibiotic therapy
|PREVI COLOR GRAM
Guide treatment options through rapid standardized Gram stain results
|BIOFIRE FILMARRAY SYSTEMS
Reduce time to optimal therapy, shorten patient stay and avoid unnecessary testing
Earlier optimization of antibiotic therapy and improved blood culture monitoring practices from an even faster and integrated time to result
|BIOFIRE BCID2 PANEL
Detect 43 targets including 10 AMR genes in about 1 hour to help optimize patient treatment decision & improve outcomes
|WASP & WASPLab
Flexible automated specimen processing and reading solution for a faster time to result with a focus only on specimens with clinical interest
|VITEK MS PRIME
Maximize daily routine workflow with enhanced productivity for faster time to reported results to positively impact patient care
Optimize therapy decisions with same-day expertized AST results
One-step isolation and direct identification of major pathogens responsible for infection
Extensive MIC information of new and existing antibiotics to further optimize patient therapy
|RAPIDEC CARBA NP
Detection and confirmation of carbapenemase-producing Gram-negative bacilli
|VIDAS BRAHMS PCT
Monitor patient response to antibiotic therapy
Optimize therapy with value-added comprehensive results and streamlined workflow
|BIOMERIEUX EPISEQ CS
Keep track of resistance and virulence genes profiles within hospital acquired infections
Optimize antimicrobial prescription with decision-support
Decision support to help prevent nosocomial infections
|VIDAS BRAHMS PCT
Support discontinuation decisions
How can we help the AMS Committee?
bioMérieux can support you all along your AMS journey with a dedicated offer for AMS Committee members to start an AMS Program or help you to go to the next level and encourage prescription guideline compliance. Here’s what you can do:
Aggregate data for resistance patterns within organism occurrence and cumulative antibiogram
|MEDICAL EDUCATION MODULES
Showcase the medical and economic value of in vitro diagnostics to support AMS to clinicians and healthcare professionals in collaboration with the microbiology laboratory
Aggregate data efficiently to capitalize on hospital resistance within microbiology data and antibiotic consumption data
|MEDICAL EDUCATION MODULES
Provide Medical Education Modules on AMS actions/interventions to support AMS to clinicians and healthcare professionals in collaboration with the microbiology laboratory
Additional Resources on Antimicrobial Stewardship
Check out our:
- Review on Antimicrobial Resistance. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations.
Available at https://amr-review.org/sites/default/files/AMR Review Paper - Tackling a crisis for the health and wealth of nations_1.pdf.
- WHO report on Antimicrobial resistance crisis.
Available at https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis